NASDAQ-listed Enveric Biosciences is merging with private psychedelics company, Magic Med Industries.
Articles
Biotech revolution on horizon could change mental health treatment
There’s a psychedelic revolution on the horizon that could change mental health treatment.
MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System
MindMed executes an MOU to access the drug delivery system of Israel-based Nextage Therapeutics.
Texas Senate Approves Psychedelics And Marijuana Concentrates Bills
The Texas Senate has approved House-passed bills to reduce criminal penalties for possessing marijuana concentrates and require the state to study the therapeutic potential of psychedelics like psilocybin and MDMA.
Robust Capital Flows Continue For Private Psychedelics Companies
Public psychedelics companies have radically scaled-back capital raising due to low share prices. But institutional investors are still pumping large amounts of cash into private players.
Wesana Health Expands Research Leadership Team with Mark Wingertzahn, PhD as Chief Scientific Officer
Wesana's new Chief Scientific Officer has deep experience in the pharmaceutical industry with Pfizer and GSK.
MindMed Announces the Approval of Mescaline Study
Mindmed's drug R&D is broadening to include mescaline, after approval by a Swiss ethics committee of a new mescaline-based study.
Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms
Cybin's 12th patent application further supports the company's novel molecule development.
Former Senate Majority Leader Tom Daschle Appointed Special Adviser to Field Trip Health Ltd.
Field Trip appoints a former high-ranking Democrat as a Special Advisor to the company.
Use of hallucinogens linked to risk seeking, emotional dysregulation in youth and college students
Hallucinogens benefit from somewhat greater acceptance than many other hard drugs, no doubt due in part to the fact that classic hallucinogens like LSD tend to be less harmful and are less likely to lead to physical dependence.
Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer
MINDCURE announces the addition of Dr. Joel Raskin as its new Chief Medical Officer. Experience includes leadership positions with drug developer, Eli Lilly & Co.
Montana Adult-Use Cannabis Legalization Bill, HB 701, Officially Signed
Governor Greg Gianforte on Tuesday signed the Montana adult-use cannabis bill that will establish a newly formed recreational marijuana program in the state, months after voters in Big Sky country approved a measure to legalize pot.
Texas Senate Advances Bill To Study Healing Potential Of Psychedelics Like Psilocybin and MDMA
A Texas Senate committee on Wednesday unanimously approved a House-passed bill that would require the state to conduct a study into the therapeutic potential of psychedelics like psilocybin and MDMA.
Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update Strategic Partnerships Expand Drug Development Capabilities to More Efficiently and Rapidly Lead the Next Generation of Psychedelic-Assisted Therapeutics
Mydecine reports a net loss of CAD$5.2 million for Q1 2021, with cash and cash equivalents of CAD$11.3 million at the end of the quarter.
Novamind Opens Client Care Center to Support High Demand for Treatments
Novamind is adding a second Client Care Center as it expands its clinic network from four to eight locations.